Article

MIR29B regulates expression of MLLT11 (AF1Q), an MLL fusion partner, and low MIR29B expression associates with adverse cytogenetics and poor overall survival in AML

University of Colorado Cancer Center, University of Colorado-Denver, Aurora, CO, USA.
British Journal of Haematology (Impact Factor: 4.71). 06/2011; 153(6):753-7. DOI: 10.1111/j.1365-2141.2011.08662.x
Source: PubMed

ABSTRACT

MLLT11, an MLL fusion partner, is a poor prognostic biomarker for paediatric acute myeloid leukaemia (AML), adult normal cytogenetics AML, and adult myelodysplastic syndrome. MLLT11 is highly regulated during haematopoietic progenitor differentiation and development but its regulatory mechanisms have not been defined. In this study, we demonstrate by transfection experiments that MIR29B directly regulates MLLT11 expression in vitro. MIR29B expression level was also inversely related to MLLT11 expression in a cohort of 56 AML patients (P<0·05). AML patients with low MIR29B/elevated MLLT11 expression had poor overall survival (P=0·038). Therefore, MIR29B may be a potential prognostic biomarker for AML patients.

Download full-text

Full-text

Available from: Jino Park, May 04, 2015
  • Source
    • "The emergence of miRNA research opens a new venue for early and accurate determination of AML pathogenesis, diagnosis and prognosis. For example, high miR-29b expression was correlated with a favorable overall survival and effective clinical response to decitabine in AML patients [47], [48]. The miR-181 family expression signature was associated with CEBPA mutational status, and the miR-181a-5p and miR-181b-5p expression levels were inversely associated with event-free survival in cytogenetically normal AML patients with high molecular risk [4], [49]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Acute myeloid leukemia (AML) is the most common acute leukemia in adults. The disease is characterized by various cytogenetic and molecular abnormalities with distinct prognoses and gene expression profiles. Emerging evidence has suggested that circulating microRNAs (miRNAs) could serve as noninvasive biomarkers for cancer detection; however, little is known about circulating miRNA profiles in AML patients. In this study, a genome-wide serum miRNA expression analysis was performed using Solexa sequencing for initial screen, followed by validation with real-time PCR assays. The analysis was conducted on training and verification sets of serum samples from 140 newly diagnosed AML patients and 135 normal adult donors. After a two-phase selection and validation process, 6 miRNAs, miR-10a-5p, miR-93-5p, miR-129-5p, miR-155-5p, miR-181b-5p and miR-320d, were found to have significantly different expression levels in AML compared with control serum samples. Furthermore, unsupervised clustering analysis revealed the remarkable ability of the 6-miRNA profile to differentiate between AML patients and normal controls. The areas under the ROC curve for the selected miRNAs ranged from 0.8129 to 0.9531. More importantly, miR-181b-5p levels in serum were significantly associated with overall survival. These data demonstrated that the expression patterns of circulating miRNAs were systematically altered in AML and miR-181b-5p may serve as a predictor for overall survival in AML patients.
    Full-text · Article · Feb 2013 · PLoS ONE
  • Source
    • "An increase in AF1q mRNA levels has been shown in retinoic acid (RA)-responsive neuroblastoma cells after exposure to the retinoid, thus identifying AF1q as a RA-target gene [14]. More recently, it has been demonstrated that AF1q mRNA expression is directly regulated by microRNA29b [15], whereas the protein is subjected to ubiquitin-mediated degradation by the proteasome in the centrosomal area [16]. AF1q was originally defined as an oncogenic factor implicated in a translocation t(1;11)(q21;q23) responsible for cases of leukemia [13]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Fenretinide (4-HPR) is a synthetic retinoid that exhibits potent antitumor and chemopreventive activities against different malignancies, including ovarian tumors. We previously showed that in ovarian cancer cells, 4-HPR induces apoptosis through a signaling cascade starting from reactive oxygen species (ROS) generation and involving endoplasmic reticulum (ER) stress response, Jun N-terminal Kinase (JNK) activation, and induction of the proapoptotic PLAcental Bone morphogenetic protein (PLAB). Since recent studies have shown that the oncogene ALL1-fused from chromosome 1q (AF1q), a retinoic acid target gene, is implicated in apoptosis induction by several therapeutic agents, we investigated its possible involvement in the apoptosis induced by 4-HPR in ovarian cancer cells.
    Full-text · Article · Jul 2012 · PLoS ONE
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In the relatively short period of time since their discovery, microRNAs have been shown to control many important cellular functions such as cell differentiation, growth, proliferation and apoptosis. In addition, microRNAs have been demonstrated as key drivers of many malignancies and can function as either tumour suppressors or oncogenes. The haematopoietic system is not outside the realm of microRNA control with microRNAs controlling aspects of stem cell and progenitor self-renewal and differentiation, with many, if not all, haematological disorders associated with aberrant microRNA expression and function. In this review, we focus on the current understanding of microRNA control of haematopoiesis and detail the evidence for the contribution and clinical relevance of aberrant microRNA function to the characteristic block of differentiation in acute myeloid leukaemia.
    Preview · Article · Jan 2012 · Journal of Cellular and Molecular Medicine
Show more